The forecasted sales for cardiovascular system medicines in Sweden indicate a gradual decline from 2024 to 2028. In 2024, the sales are predicted to be 5.2% of the total sales, decreasing by 3.8% in 2025 to 5%, then further dropping to 4.8% in 2026. The trend continues with a year-on-year decline of 4.2% in 2027, reaching 4.6%, and finally slowing down to a 2.2% decrease by 2028, stabilizing at 4.5%. The last actual figure for 2023 was slightly higher, indicating a downward trend over the forecast period.

Key future trends to watch for:

Introduction of new and innovative cardiovascular treatments.
Changes in healthcare policies and reimbursement scenarios in Sweden.
Potential impacts of emerging technologies and personalized medicine.
Demographic shifts and the increasing prevalence of lifestyle-related cardiovascular diseases.
Economic factors influencing healthcare spending and budget allocations.